Scholars Central

Conference abstract

MHC Class I TCR driven CD4+ antitumor T Cells for cancer immunotherapy.

Authors: Arvind Chhabra

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Recently, interest in semiallogeneic vaccines has been increasing, as shown by the publication of successful preclinical and clinical studies by us and others that validate this immunotherapeutic approach to cancer, viral diseases such as the acquired immunodefi ciency syndrome and neurological diseases. Th ese reports indicate that treatment with semiallogeneic vaccines can induce a specifi c immune response against various tumors and against the human immunodefi ciency virus. Experimental studies using inbred mice and their syngeneic tumors initially established that 1) inoculation of s emiallogeneic cell hybrids (derived from the fusion of syngeneic tumor cells with an allogeneic cell line) protects the animal host from subsequent lethal challenges with unmodifi ed syngeneic tumor cells; 2) adoptive transfer of immunity required T lymphocytes; and 3) the enhanced immunity was not the result of an allogeneic eff ect per se, because the tumor-associated antigens and alloantigens needed to be on the same cell (the hybrid). Human studies with semiallogeneic cell hybrids have focused on the use of therapeutic vaccines for cancer. Because of the many technical problems associated with obtaining suffi cient amounts of autologous tumor cells for the preparation of patient-specifi c cancer vaccines, and because of evidence that allogeneic eff ects may enhance the antitumor immune response, it seemed reasonable to combine the best of both approaches (autologous and allogeneic), because semiallogeneic hybrids focus allorecognition and major histocompatibility complex self-restricted recognition on the same cell and, therefore, in the same microenvironment. Our studies demonstrate the feasibility of using semiallogenic vaccines to treat a variety of tumors and neurological disease.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Vaccines & Vaccination.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Vaccines & Vaccination
  • SubjectVaccines & Immunisation
  • BylineArticles whose byline prints “Arvind Chhabra”